News for Health Catalyst, Inc. (HCAT)

On July 9, 2025, the stock of Health Catalyst (HCAT) saw a noteworthy update from the financial services firm Evercore ISI Group. Analyst Elizabeth Anderson has

BTIG has revised its rating for Health Catalyst (HCAT), shifting it from a "Buy" to "Neutral," while choosing not to assign a specific price target. The decisio

Health Catalyst's Ignite platform drives growth, higher margins, and revenue acceleration. Click here to read more on HCAT and why I've rated it as a Buy.

**media[631557]**

Health Catalyst, Inc. (NASDAQ:HCAT) Q1 2025 Earnings Conference Call May 7, 2025 5:00 PM ETCompany ParticipantsJack Knight - Vice President, Investor...

The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

**media[618040,618041]**

Health Catalyst (HCAT) has formed a strategic alliance with Microsoft aimed at advancing the operational, clinical, and financial outcomes for healthcare organi

PR NewswireSALT LAKE CITY, April 29, 2025 Health Catalyst's Improvement Expertise Built on Microsoft Azure and Azure AI Foundry to Drive Reliable Insight a

Health Catalyst (HCAT) partners with Microsoft to speed up AI adoption in healthcare. Healthcare.AI and Health Catalyst Ignite are now available on Micr

Citi has revised its price target for Health Catalyst (HCAT), reducing it from $7 to $6.50 while maintaining a Buy rating on the company's shares. This adjustme

SALT LAKE CITY, April 17, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", HCAT), a leading provider of data and analytics technology and s

KeyBanc analyst Scott Schoenhaus has revised the price target for Health Catalyst (HCAT), decreasing it from $7 to $5. Despite this adjustment, the firm maintai

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the appointment of Robert

Health Catalyst reports strong growth with AI-driven efficiencies, forecasting $335M in revenue for 2025. Click here to find out why HCAT stock is a Buy.

Investors need to pay close attention to Health Catalyst (HCAT) stock based on the movements in the options market lately.

PR NewswireSALT LAKE CITY, March 11, 2025 SALT LAKE CITY, March 11, 2025 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading

BRENTWOOD, Tenn., March 07, 2025 (GLOBE NEWSWIRE) -- CoreCivic, Inc. (: CXW) (CoreCivic or the Company) announced today that, effective March 17, 2025, Dawn S